In today's ACT Brief, we examine understanding the patient journey from end to end, whether decentralization reduces site burden or just shifts it, and why nine European drugmakers are sounding urgent alarms.
|Articles|November 1, 2018
CRF Health sees eCOA Solutions Secure 15 Global Dermatology Trials
Advertisement
CRF Health, a provider of patient-centered eSource technology solutions, announced the awarding of two new contracts by top-20 pharma companies, which will see the company’s eCOA solutions used to capture patient reported outcomes in 15 global dermatology trials including a range of Phase II-IV studies.
Read the full release
Advertisement
Related to this article
Decentralized trial models have demonstrated real gains in enrollment performance and patient access, but operational switching costs, fragmented technology stacks, and unresolved gaps in the patient-site relationship raise a question the industry has been slow to confront directly.
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why truly understanding the patient journey from beginning to end—and building that understanding into both study design and data collection tools—remains one of the industry's most important unfinished tasks.
In today's ACT Brief, we examine technology's real role in patient-site collaboration, why AI pilot failures stem from organization not innovation, and Novo's weight-loss drug results in competitive comparison.
Most AI pilots in drug development fail not from poor technology but from lack of strategic prioritization, organizational readiness, integrated data infrastructure, and disciplined governance, making success dependent on business discipline rather than technical capability.
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't usability alone—it's making it easier for patients and sites to interact more effectively with each other.
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Moving Beyond Disappointing Pilots: Scaling Adoption of AI-Enablement in Drug Development
2
Is Decentralization Actually Reducing Site Burden, or Just Moving It?
3
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
4
DPHARM 2026: The Patient Journey Gap That Study Design Still Hasn't Solved
5